Brief: Dr. Lal Pathlabs Says COVID-19 Contributed 17% To Revenue In Q2 FY21
06/11/2020 09:40
Nov 6 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS :
* COVID-19 CONTRIBUTED 17% TO REVENUE IN Q2 FY21 WITH
308,000
RTPCR TESTS
Source text: (https://bit.ly/3oWNzG1)
Further company coverage: DLPA.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dr. Lal PathLabs
See all newsBrief: Lal Pathlabs Says Unit Acquired Remaining 30% Equity Stake In Centrapath Labs Private Limited
India's Dr Lal PathLabs rises as Axis Securities initiates with 'buy'
India's Dr Lal PathLabs rises; analysts back SN Genelab deal
Brief: Lal Pathlabs Says Subsidiary Incorporated Dr Lal Pathlabs Indomed In Tashkent, Uzbekistan
India's Dr Lal PathLabs jumps to 4-year high after quarterly profit rise